טוען...
A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers
This is a randomized, double‐blind, single‐dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS‐503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3 mg/kg intravenous dose of eithe...
שמור ב:
| הוצא לאור ב: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5368956/ https://ncbi.nlm.nih.gov/pubmed/28357118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.286 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|